A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Didanosine, Drug Therapy, Combination, Stavudine, HIV Protease Inhibitors, CD4 Lymphocyte Count, Nelfinavir, Reverse Transcriptase Inhibitors, Self Care, Anti-HIV Agents, Viral Load, efavirenz, Treatment Naive
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are HIV-positive. Are at least 13 years old (consent is required if you are under 18). Have a CD4 count of at least 200 cells/mm3 within 30 days of study entry. Have never taken anti-HIV drugs. Agree to practice effective methods of birth control. Exclusion Criteria Patients will not be eligible for this study if they: Have cancer (except for Kaposi's sarcoma) that requires treatment. Have a history of hepatitis or pancreatitis. Have peripheral neuropathy. Have an alcohol abuse problem. Are pregnant or breast-feeding. Are taking certain medications, such as rifabutin, rifampin, interleukin, or chemotherapy.
Sites / Locations
- UCSD
- Univ of Texas Southwestern Med Ctr